SCHEMBL644238

SCHEMBL644238

Cn1ccc(NC(=O)c2cc(OCC(=O)c3ccc(CO)cc3)c3c(c2)OC(C)(C)C3)n1

nearest known ligand 0.56

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
GCK P35557 11/20 0.56
NPC1 O15118 2/20 0.40
RAB9A P51151 2/20 0.40
KCNH2 Q12809 1/20 0.38
NOTUM Q6P988 1/20 0.38
IRAK4 Q9NWZ3 1/20 0.37
HPGDS O60760 1/20 0.36
GABRA5 P31644 1/20 0.36
ALDH1A1 P00352 1/20 0.36
LMNA P02545 1/20 0.36
MAPK1 P28482 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL644552 0.88 GCK (0.55) GCKNPC1RAB9ANOTUMIRAK4
SCHEMBL645839 0.87 GCK (0.56) GCKNPC1RAB9ANOTUMIRAK4
SCHEMBL9923480 0.85 GCK (0.54) GCKNPC1RAB9ANOTUMIRAK4
SCHEMBL644899 0.85 GCK (0.62) GCKNPC1RAB9AIRAK4HPGDS
SCHEMBL644304 0.84 GCK (0.64) GCKNPC1RAB9AKCNH2
SCHEMBL642856 0.83 GCK (0.58) GCKNPC1RAB9ANOTUMIRAK4
SCHEMBL644027 0.82 GCK (0.58) GCKNPC1RAB9AKCNH2
SCHEMBL643951 0.82 GCK (0.59) GCKNPC1RAB9AIRAK4HPGDS
SCHEMBL2643330 0.81 KDM4E (0.39) NPC1RAB9AALDH1A1LMNAMAPK1
SCHEMBL2663492 0.80 GCK (0.57) GCKNPC1RAB9AKCNH2IRAK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2463283-B1 Fused phenyl Amido heterocyclic compounds for the prevention and treatment of glucokinase-mediated diseases PFIZER PROD INC (US) 2014-06-11 EP disclosed
EP-2010520-B1 HETEROBICYCLIC AMIDES FOR THE PREVENTION AND TREATMENT OF GLUCOKINASE-MEDIATED DISEASES PFIZER PROD INC (US) 2012-09-12 EP disclosed
US-8119624-B2 Fused phenyl amido heterocyclic compounds PFIZER INC. (US) 2012-02-21 US disclosed
US-8119624-B2 Fused phenyl amido heterocyclic compounds PFIZER INC. (US) 2012-02-21 US disclosed
US-8119624-B2 Fused phenyl amido heterocyclic compounds PFIZER INC. (US) 2012-02-21 US disclosed
US-20110039821-A1 Fused Phenyl Amido Heterocyclic Compounds PFIZER INC 2011-02-17 US disclosed
US-20110039821-A1 Fused Phenyl Amido Heterocyclic Compounds PFIZER INC 2011-02-17 US disclosed
US-20110039821-A1 Fused Phenyl Amido Heterocyclic Compounds PFIZER INC 2011-02-17 US disclosed
US-7842713-B2 Fused phenyl amido heterocyclic compounds PFIZER INC (US) 2010-11-30 US disclosed
US-7842713-B2 Fused phenyl amido heterocyclic compounds PFIZER INC (US) 2010-11-30 US disclosed
US-20080280875-A1 FUSED PHENYL AMIDO HETEROCYCLIC COMPOUNDS PFIZER INC. 2008-11-13 US disclosed
US-20080280875-A1 FUSED PHENYL AMIDO HETEROCYCLIC COMPOUNDS PFIZER INC. 2008-11-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110039821-A1 Fused Phenyl Amido Heterocyclic Compounds GCK, GCKR, HK1 GCK 1/4885NPC1 1969/4885RAB9A 2949/4885
US-20080280875-A1 FUSED PHENYL AMIDO HETEROCYCLIC COMPOUNDS GCK, GCKR, HK1 GCK 1/4885NPC1 1969/4885RAB9A 2949/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.